Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12609000203257
Ethics application status
Approved
Date submitted
18/02/2009
Date registered
22/04/2009
Date last updated
12/11/2018
Date data sharing statement initially provided
12/11/2018
Type of registration
Retrospectively registered
Titles & IDs
Public title
Dose-Finding Study of the Relationship between Oral Vitamin D3 and Serum 25-Hydroxy Vitamin D3 Concentration. Protocol: ODS25
Query!
Scientific title
Dose-Finding Study of the Relationship between Oral Vitamin D3 and Serum 25-Hydroxy (OH) Vitamin D3 Concentration to achieve a target serum 25-OH vitamin D3 concentration in patients attending rheumatology outpatient clinics. Protocol: ODS25
Query!
Secondary ID [1]
296577
0
The trial is no longer active
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ODS25
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Nil
4353
0
Query!
Condition category
Condition code
Musculoskeletal
4941
4941
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Oral vitamin D3 at starting dose of 20,000U per week followed by dose adjustment 6-weekly to achieve a target serum 25-OH vitamin D3 concentration of 140-180 nmol/L. Each participant will be on trial for 12 months, regardless of whether or not they have achieved the target serum 25-OH vitamin D3 levels.
Query!
Intervention code [1]
4400
0
Treatment: Other
Query!
Comparator / control treatment
Nil-open label single arm dose finding study
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
5473
0
The primary outcome is descriptive. It will document the range of oral vit D3 dose(s) required to achieve a serum concentration of 140-180 nmol/L 25-OH vitamin D3 at two successive 6-weekly measures. The serum 25-OH vitamin D3 will be determined by radioimmunoassay.
Query!
Assessment method [1]
5473
0
Query!
Timepoint [1]
5473
0
The achievement of target concentrations of serum 25-OH vitamin D3 at two successive 6-weekly measures is expected to occur at different times in different participants. However, all participants will continue on-study for 12 months after the initial oral vitamin D3 administration.
Query!
Secondary outcome [1]
9215
0
Nil
Query!
Assessment method [1]
9215
0
Query!
Timepoint [1]
9215
0
N/A
Query!
Eligibility
Key inclusion criteria
Patients attending rheumatology outpatient clinics, serum 25-hydroxy vitamin D3 < 100 nmol/L
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Pregnancy and lactation, women of childbearing age not using contraception, history of hypercalcemia or parathyroid disease, chronic renal failure with evidence of renal stones (calculated creatinine clearance must be > 50 ml/min by the Cockcroft-Gault equation), sarcoidosis with hypercalcemia, unsuppressed Pagets disease, metastatic bone disease, calcium pyrophosphate deposition disease (pseudogout), heterogenous calcification
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Withdrawn
Query!
Reason for early stopping/withdrawal
Lack of funding/staff/facilities
Query!
Date of first participant enrolment
Anticipated
30/03/2009
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
30
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Funding & Sponsors
Funding source category [1]
4814
0
Self funded/Unfunded
Query!
Name [1]
4814
0
Nil
Query!
Address [1]
4814
0
Nil
Query!
Country [1]
4814
0
Query!
Funding source category [2]
301156
0
Self funded/Unfunded
Query!
Name [2]
301156
0
Query!
Address [2]
301156
0
Query!
Country [2]
301156
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Michael James
Query!
Address
Rheumatology Unit
Royal Adelaide Hospital
North Tce
Adelaide SA 5000
Query!
Country
Australia
Query!
Secondary sponsor category [1]
4092
0
None
Query!
Name [1]
4092
0
Query!
Address [1]
4092
0
Query!
Country [1]
4092
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
6862
0
Royal Adelaide Hospital Research Ethics Committee
Query!
Ethics committee address [1]
6862
0
Royal Adelaide Hospital, North Terrace, Adelaide SA 5000
Query!
Ethics committee country [1]
6862
0
Australia
Query!
Date submitted for ethics approval [1]
6862
0
Query!
Approval date [1]
6862
0
25/02/2009
Query!
Ethics approval number [1]
6862
0
090211
Query!
Summary
Brief summary
The study will determine the range of oral doses of vitamin D that are necessary to raise blood levels of vitamin D to an extent that may have positive effects in patients with rheumatoid arthritis. This study will not examine rheumatoid arthritis outcomes, but the results will be used to plan a later study with rheumatoid patients to examine the effects of vitamin D.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
29305
0
Prof Les Cleland
Query!
Address
29305
0
Rheumatology Unit
Royal Adelaide Hospital
North Tce
Adelaide
SA 5000
Australia
Query!
Country
29305
0
Australia
Query!
Phone
29305
0
+61-8-8222 5190
Query!
Fax
29305
0
Query!
Email
29305
0
[email protected]
Query!
Contact person for public queries
Name
12552
0
Prof Les Cleland
Query!
Address
12552
0
Rheumatology Unit
Royal Adelaide Hospital
North Tce
Adelaide SA 5000
Query!
Country
12552
0
Australia
Query!
Phone
12552
0
+61-8-82225190
Query!
Fax
12552
0
Query!
Email
12552
0
[email protected]
Query!
Contact person for scientific queries
Name
3480
0
Prof Les Cleland
Query!
Address
3480
0
Rheumatology Unit
Royal Adelaide Hospital
North Tce
Adelaide SA 5000
Query!
Country
3480
0
Australia
Query!
Phone
3480
0
+61-8-82225190
Query!
Fax
3480
0
Query!
Email
3480
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF